Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma

Cancer immunology research

Volumn 2, Issue 8, 2014, Pages 725-731

  Noonan, Kimberly A ^a   Ghosh, Nilanjan ^a   Rudraraju, Lakshmi ^a   Bui, Marilyn ^a   Borrello, Ivan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOLINE DERIVATIVE; CLARITHROMYCIN; DEXAMETHASONE; IL4R PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERLEUKIN 4 RECEPTOR ALPHA; LENALIDOMIDE; PHOSPHODIESTERASE V INHIBITOR; TADALAFIL; THALIDOMIDE;

ANALOGS AND DERIVATIVES; BONE MARROW CELL; CASE REPORT; DRUG EFFECTS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; T LYMPHOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOLINES; CLARITHROMYCIN; DEXAMETHASONE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOID CELLS; PHOSPHODIESTERASE 5 INHIBITORS; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84910071057     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0213     Document Type: Article

References (0)